Enveda’s Oral Candidate ENV-294 Shows Early Promise in Atopic Dermatitis
As reported on Business Wire, Enveda, a clinical-stage biotechnology company focused on discovering novel small-molecule medicines, has reported encouraging results from a Phase 1b study evaluating its investigational therapy ENV-294…